Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

FENS 2020 | The under-representation of females in research: impact in drug development

Christina Dalla • 15 Jul 2020
FENS 2020
Alzheimer’s Disease Dementia Psychiatric Disorders

Christina Dalla, PhD, National and Kapodistrian University of Athens, Athens, Greece, outlines how the lack of female representation in neuropsychiatric research has impacted drug development. Prof. Dalla believes that this mismatch has contributed to the failure of discovering new promising drugs. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Christina Dalla

Lack of female representation in neuropsychiatric research
1:18
Lack of female representation in neuropsychiatric research
Christina Dalla • 15 Jul 2020
Gender-oriented treatments for neuropsychiatric disorders
1:05
Gender-oriented treatments for neuropsychiatric disorders
Christina Dalla • 15 Jul 2020
The importance of sex differences in neuroscience
1:20
The importance of sex differences in neuroscience
Christina Dalla • 15 Jul 2020
Sex differences in Alzheimer’s disease
2:54
Sex differences in Alzheimer’s disease
Christina Dalla • 15 Jul 2020

Related Videos

Bridging stroke and memory care to improve outcomes in cerebral small vessel disease
2:35
Bridging stroke and memory care to improve outcomes in cerebral small vessel disease
Joanna Wardlaw • 22 Oct 2026
Neuropixels, AI and theory: the future of understanding brain network dynamics
2:11
Neuropixels, AI and theory: the future of understanding brain network dynamics
Edvard I. Moser • 22 Oct 2026
The overlap between prolonged grief and insomnia: symptom trajectories and risk factors
3:14
The overlap between prolonged grief and insomnia: symptom trajectories and risk factors
Ali Amidi • 21 Oct 2026
Alpha-synuclein and amyloid copathology in iRBD: prevalence and clinical significance
0:59
Alpha-synuclein and amyloid copathology in iRBD: prevalence and clinical significance
Gerard Mayà Casalprim • 22 Oct 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals